• Molecular NameCarbenoxolone
  • SynonymNA
  • Weight570.767
  • Drugbank_IDN/A
  • ACS_NO5697-56-3
  • Show 3D model
  • LogP (experiment)7.1
  • LogP (predicted, AB/LogP v2.0)6.95
  • pka6.7, 7.1
  • LogD (pH=7, predicted)2.4
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.12
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds6
  • TPSA117.97
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA synthetic derivative of glycyrrhizinic acid, is a licensed drug (in the UK) for oesophageal ulceration and inflammation. Other uses include treatment of oral and perioral lesions.
  • Absorption_valueN/A
  • Absorption (description)Carbenoxolone is rapidly and almost completely absorbed after oral administration
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.0
  • Volume of distribution (VD)0.1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life13 h
  • ExcretionIt is almost entirely eliminated in the faeces via the bile, less than 5% being excreted in the urine. Carbenoxolone is excreted mainly as the glucuronide conjugate together with small amounts as the sulfate conjugate of β-glycyrrhetic acid (enoxolone).
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityLD50>=1000 (mouse)
  • LD50 (rat)N/A
  • LD50 (mouse)N/A